Healthcare provider profile · identity verified

Nicholas M Lopez, M.D.

Allopathic & Osteopathic Physicians|Family Medicine · HOLLAND, OH · NPI 1932107562

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Nicholas M Lopez, M.D. received $258.34 in general payments during 2025 across 4 reported records.

AstraZeneca Pharmaceuticals LP accounted for 47.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$258.34

4 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$122.11	47.3%	1	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$92.11	35.6%	1	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$24.43	9.5%	1	2025
Exact Sciences Corporation	Unresolved — no canonical attribution shown	$19.69	7.6%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$258.34	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$122.11	1	2025
Source payment records 2025-02-26 · AstraZeneca Pharmaceuticals LP · $122.11 · Open Payments source
AREXVY Normalized: arexvy	Biological	GlaxoSmithKline, LLC.	$92.11	1	2025
Source payment records 2025-02-19 · GlaxoSmithKline, LLC. · $92.11 · Open Payments source
UBRELVY Normalized: ubrelvy	Drug	ABBVIE INC.	$24.43	1	2025
Source payment records 2025-03-13 · ABBVIE INC. · $24.43 · Open Payments source
Cologuard Collection Kit Normalized: cologuard collection kit	Device	Exact Sciences Corporation	$19.69	1	2025
Source payment records 2025-03-17 · Exact Sciences Corporation · $19.69 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	224	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	ARMOUR THYROID open payments reported associated product	CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088	Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	39	13
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	42	12
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	224	53
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	62	22

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	790	203
Metoprolol Succinate	Metoprolol Succinate	721	198
Irbesartan	Irbesartan	555	140
Amlodipine Besylate	Amlodipine Besylate	537	152
Rosuvastatin Calcium	Rosuvastatin Calcium	487	133
Pantoprazole Sodium	Pantoprazole Sodium	458	105
Lisinopril	Lisinopril	423	100
Omeprazole	Omeprazole	409	116
Montelukast Sodium	Montelukast Sodium	370	106
Levothyroxine Sodium	Levothyroxine Sodium	337	86
Furosemide	Furosemide	336	93
Gabapentin	Gabapentin	288	71
Famotidine	Famotidine	280	95
Metformin Hcl	Metformin Hcl	238	56
Alprazolam	Alprazolam	236	56
Potassium Chloride	Potassium Chloride	234	64
Albuterol Sulfate Hfa	Albuterol Sulfate	231	67
Farxiga	Dapagliflozin Propanediol	224	53
Cefadroxil	Cefadroxil	220	144
Tizanidine Hcl	Tizanidine Hcl	214	85
Losartan Potassium	Losartan Potassium	207	55
Metformin Hcl Er	Metformin Hcl	206	57
Glimepiride	Glimepiride	193	56
Atenolol	Atenolol	191	52
Hydrochlorothiazide	Hydrochlorothiazide	184	61
Clopidogrel	Clopidogrel Bisulfate	180	41
Nifedipine Er	Nifedipine	169	49
Simvastatin	Simvastatin	167	40
Duloxetine Hcl	Duloxetine Hcl	166	29
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	166	44
Zolpidem Tartrate	Zolpidem Tartrate	162	36
Tamsulosin Hcl	Tamsulosin Hcl	161	40
Escitalopram Oxalate	Escitalopram Oxalate	150	39
Azithromycin	Azithromycin	149	114
Trazodone Hcl	Trazodone Hcl	147	39
Clonazepam	Clonazepam	143	28
Pravastatin Sodium	Pravastatin Sodium	143	36
Mounjaro	Tirzepatide	132	25
Meloxicam	Meloxicam	127	37
Eliquis	Apixaban	126	23
Jardiance	Empagliflozin	122	19
Buspirone Hcl	Buspirone Hcl	121	35
Topiramate	Topiramate	118	24
Pregabalin	Pregabalin	107	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	106	39
Carvedilol	Carvedilol	99	29
Ozempic	Semaglutide	98	20
Pioglitazone Hcl	Pioglitazone Hcl	98	24
Ropinirole Hcl	Ropinirole Hcl	95	19
Fluoxetine Hcl	Fluoxetine Hcl	92	17
Metoprolol Tartrate	Metoprolol Tartrate	92	20
Lorazepam	Lorazepam	91	20
Ondansetron Odt	Ondansetron	91	37
Tramadol Hcl	Tramadol Hcl	88	31
Allopurinol	Allopurinol	87	23
Trulicity	Dulaglutide	85	17
Memantine Hcl	Memantine Hcl	84	18
Finasteride	Finasteride	83	24
Mirtazapine	Mirtazapine	81	19
Bumetanide	Bumetanide	78	22
Ibuprofen	Ibuprofen	77	29
Sertraline Hcl	Sertraline Hcl	76	15
Ezetimibe	Ezetimibe	75	21
Fluticasone Propionate	Fluticasone Propionate	75	41
Quetiapine Fumarate	Quetiapine Fumarate	72	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	70	11
Meclizine Hcl	Meclizine Hcl	69	23
Doxycycline Hyclate	Doxycycline Hyclate	68	45
Mupirocin	Mupirocin	68	39
Tresiba Flextouch U-100	Insulin Degludec	68	15
Bupropion Xl	Bupropion Hcl	67	22
Methylprednisolone	Methylprednisolone	66	54
Citalopram Hbr	Citalopram Hydrobromide	65	12
Doxepin Hcl	Doxepin Hcl	62	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	62	22
Ketoconazole	Ketoconazole	61	43
Xarelto	Rivaroxaban	61	12
Dicyclomine Hcl	Dicyclomine Hcl	59	20
Januvia	Sitagliptin Phosphate	58	suppressed
Levofloxacin	Levofloxacin	56	34
Hydralazine Hcl	Hydralazine Hcl	55	16
Celecoxib	Celecoxib	51	12
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	50	suppressed
Sucralfate	Sucralfate	50	22
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	49	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	49	11
Fluconazole	Fluconazole	47	34
Levetiracetam	Levetiracetam	46	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	46	26
Prednisone	Prednisone	46	36
Diclofenac Sodium Er	Diclofenac Sodium	45	18
Donepezil Hcl	Donepezil Hcl	43	11
Dutasteride	Dutasteride	43	12
Metolazone	Metolazone	43	16
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	42	14
Lidocaine	Lidocaine	42	14
Synthroid	Levothyroxine Sodium	42	12
Nystatin	Nystatin	41	21
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	41	suppressed
Alendronate Sodium	Alendronate Sodium	40	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	40	suppressed
Breo Ellipta	Fluticasone/Vilanterol	39	suppressed
Linzess	Linaclotide	39	13
Vascepa	Icosapent Ethyl	38	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	36	suppressed
Naproxen	Naproxen	35	17
Tresiba Flextouch U-200	Insulin Degludec	35	suppressed
Warfarin Sodium	Warfarin Sodium	35	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	33	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	33	14
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Spironolactone	Spironolactone	32	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	31	27
Droplet Pen Needle	Pen Needle, Diabetic	30	14
Myrbetriq	Mirabegron	30	suppressed
Paroxetine Hcl	Paroxetine Hcl	30	11
Hydrocortisone	Hydrocortisone	29	15
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	29	suppressed
Baclofen	Baclofen	28	suppressed
Diclofenac Sodium	Diclofenac Sodium	27	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	26	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	14
Primidone	Primidone	26	suppressed
Trintellix	Vortioxetine Hydrobromide	26	suppressed
Humalog Kwikpen U-100	Insulin Lispro	25	15
Temazepam	Temazepam	25	suppressed
Colchicine	Colchicine	23	suppressed
Icosapent Ethyl	Icosapent Ethyl	23	13
Carbidopa-Levodopa	Carbidopa/Levodopa	22	suppressed
Novolog Flexpen	Insulin Aspart	22	suppressed
Rybelsus	Semaglutide	22	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	21	21
Glipizide Er	Glipizide	21	suppressed
Midodrine Hcl	Midodrine Hcl	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	13
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	20	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	18
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	18	suppressed
Glipizide	Glipizide	18	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	suppressed
Terbinafine Hcl	Terbinafine Hcl	18	11
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	17	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	16	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	16	13
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Premarin	Estrogens, Conjugated	16	suppressed
Ranolazine Er	Ranolazine	16	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	16	suppressed
Acyclovir	Acyclovir	15	suppressed
Cilostazol	Cilostazol	15	suppressed
Diazepam	Diazepam	15	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	13
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Sildenafil Citrate	Sildenafil Citrate	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Armour Thyroid	Thyroid,pork	14	suppressed
Fenofibric Acid	Fenofibric Acid (Choline)	14	suppressed
Lacosamide	Lacosamide	14	suppressed
Verapamil Er	Verapamil Hcl	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Haloperidol	Haloperidol	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Potassium Citrate Er	Potassium Citrate	12	suppressed
Ramipril	Ramipril	12	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	12	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Clindamycin Hcl	Clindamycin Hcl	11	suppressed
Estradiol	Estradiol	11	suppressed
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Nebivolol Hcl	Nebivolol Hcl	11	suppressed
Torsemide	Torsemide	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$258.34 · 4 records	AstraZeneca Pharmaceuticals LP	AREXVY, Cologuard Collection Kit, FARXIGA, UBRELVY	6	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error